Is Ebglyss a Biologic?
Yes, Ebglyss (lebrikizumab-lbkz) is a biologic drug. It is a humanized monoclonal antibody that targets interleukin-13 (IL-13) to treat moderate-to-severe atopic dermatitis in adults and children 12 years and older whose condition is not adequately controlled with topical therapies.[1][2]
How Does Ebglyss Work?
Ebglyss binds specifically to IL-13, a cytokine involved in type 2 inflammation that drives atopic dermatitis symptoms like itching and skin lesions. Administered via subcutaneous injection every two weeks after initial doses, it reduces inflammation at the cellular level, unlike small-molecule drugs that often target broader pathways.[1][3]
Who Makes Ebglyss and When Was It Approved?
Eli Lilly and Company manufactures Ebglyss. The FDA approved it in September 2024 as a first-line biologic option for atopic dermatitis, following positive Phase 3 trials showing significant skin clearance and itch reduction compared to placebo.[1][4]
How Does Ebglyss Compare to Other Atopic Dermatitis Biologics?
Ebglyss differs from Dupixent (dupilumab), which blocks both IL-4 and IL-13 signaling, by focusing solely on IL-13. This makes it potentially less immunosuppressive but equally effective in trials (e.g., 43% achieved clear/almost clear skin at week 16 vs. 13% on placebo). It competes with Adbry (tralokinumab), another IL-13 inhibitor, but offers a less frequent dosing schedule.[1][3][5]
| Drug | Target | Dosing | FDA Approval Year |
|------|--------|--------|-------------------|
| Ebglyss | IL-13 | Q2 weeks | 2024 |
| Dupixent | IL-4/IL-13 | Q2-4 weeks | 2017 |
| Adbry | IL-13 | Q2 weeks | 2021 |
What About Patents and Availability?
Eli Lilly holds patents on Ebglyss through at least 2037, covering the antibody composition and manufacturing process.[6] No biosimilars are expected soon due to its recent approval and data exclusivity until around 2029. List price is about $8,500 per month before discounts.[4][6]
Common Patient Questions on Side Effects and Use
Patients report conjunctivitis (7-10%), injection-site reactions, and herpes infections as main side effects, similar to other IL-13 inhibitors but less frequent than with broader biologics like Dupixent. It's not recommended during pregnancy due to limited data; live vaccines should be avoided.[1][2]
Sources:
[1] FDA Approval Letter
[2] Ebglyss Prescribing Information
[3] NEJM Phase 3 Trial
[4] Lilly Press Release
[5] Dupixent Site
[6] DrugPatentWatch.com